Importantly, ACVR1 mutant diseases have previously been responsive to the retinoic receptor agonist palovarotene, with efficacy repeated in a small cohort of DMG patients, whereby the one patient harboring an ACVR1 mutation experienced tumor stabilization for 30 weeks (168). Here, ACVR1 is linked to neoplasm.